Novartis says 82 percent of leukemia patients in remission after CAR-T

(Reuters) - An experimental cancer therapy being developed by Novartis AG eliminated an aggressive form of blood cancer in 82 percent of children and young adults treated with modified immune cells in a mid-stage trial, the company said on Saturday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news

Related Links:

This study suggests that exocrine glands can be induced from pluripotent stem cells for organ replacement regenerative therapy. Replacement of Aged Microglia Partially Reverses Cognitive Decline in Mice https://www.fightaging.org/archives/2018/10/replacement-of-aged-microglia-partially-reverses-cognitive-decline-in-mice/ Researchers here report on a compelling demonstration that shows the degree to which dysfunctional microglia contribute to age-related neurodegeneration. The scientists use a pharmacological approach to greatly deplete the microglial population and then allow it to recover naturally. The...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Abstract Tisagenlecleucel (Kymriah, Novartis Pharmaceuticals, East Hanover, NJ) is a CD19-directed genetically-modified autologous T-cell immunotherapy. On August 30, 2017, the U.S. Food and Drug Administration approved tisagenlecleucel for treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse. Approval was based on the complete remission (CR) rate, durability of CR and minimal residual disease (MRD)
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
In conclusion, HSC ageing is characterised by reduced self-renewal, myeloid and platelet HSC skewing, and expanded clonal haematopoiesis that is considered a preleukaemic state. The underlying molecular mechanisms seem to be related to increased oxidative stress due to ROS accumulation and DNA damage, which are influenced by both cell- and cell non-autonomous mechanisms such as prolonged exposure to infections, inflammageing, immunosenescence, and age-related changes in the HSC niche. Thus, HSC ageing seems to be multifactorial and we are only beginning to connect all the dots. The Price of Progress or the Waste...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
CONCLUSIONS: Response to tisagenlecleucel was associated with increased expansion across a wide dose range. These results highlight the importance of cellular kinetics in understanding determinants of response to chimeric antigen receptor T-cell therapy. PMID: 30190371 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Pediatric Blood&Cancer, EarlyView.
Source: Pediatric Blood and Cancer - Category: Cancer & Oncology Authors: Source Type: research
We report that the disruption of excitation-contraction coupling contributes to impaired force generation in the mouse model of Sod1 deficiency. Briefly, we found a significant reduction in sarcoplasmic reticulum Ca2+ ATPase (SERCA) activity as well as reduced expression of proteins involved in calcium release and force generation. Another potential factor involved in EC uncoupling in Sod1-/- mice is oxidative damage to proteins involved in the contractile response. In summary, this study provides strong support for the coupling between increased oxidative stress and disruption of cellular excitation contraction mac...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
UCLA Health has joined an important national clinical trial that uses genetic testing to match people who have acute myeloid leukemia, or AML, with new therapies. UCLA ’s hospital system is the first in California to offer people the opportunity to participate.The Beat AML Master Trial will evaluate a precision-based medicine approach to treating the disease; it will allow people with the disease to have immediate access to new treatments that are currently in development without having to try more traditional approaches first. The approach could streamline a patient ’s course of treatment and, ultimately, save...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
Curry J, Featherston S, Foglesong J, Shoberu B, Gulbis A, Mireles ME, Hafemeister L, Nguyen C, Kapoor N, Rezvani K, Neelapu SS, Shpall EJ, Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network Abstract In 2017, an autologous chimeric antigen receptor (CAR) T cell therapy indicated for children and young adults with relapsed and/or refractory CD19+ acute lymphoblastic leukaemia became the first gene therapy to be approved in the USA. This innovative form of cellular immunotherapy has been associated with remarkable response rates but is also associated with unique and often severe toxicities, which ...
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Tags: Nat Rev Clin Oncol Source Type: research
Acute Myeloid Leukemia (AML) is an aggressive malignancy that is treated using intensive cytotoxic chemotherapeutic regimens. There are limited alternative therapeutic options once the disease becomes refractory to chemotherapeutic treatment. CD33 is expressed on the surface of the vast majority of AML blasts and cells in chronic myeloid leukemia-blast crisis (CML-BC) – and is a well-validated immunotherapeutic target.  CD33 is also aberrantly expressed on a subset of T cell acute lymphoblastic leukemias (ALLs). Normal tissue expression is restricted to normal myeloid cells. Treatment of pre-B cell ALL and lymph...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
Tejpal Gupta, Sridhar Epari, Aliasgar Moiyadi, Prakash Shetty, Jayant Sastri Goda, Rahul Krishnatry, Girish Chinnaswamy, Tushar Vora, Hari Menon, Vijay Patil, Ayushi Sahay, Nazia Bano, Rakesh JalaliIndian Journal of Cancer 2017 54(4):594-600 Primary tumors of the central nervous system are relatively uncommon, comprising only 1%–2% of all neoplasms. However, they constitute the second most common type of malignancy in children (after leukemia) and the leading cause of cancer-related morbidity and mortality in children and young adults worldwide. Globally, there is substantial variability with nearly five-fol...
Source: Indian Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Cancer in Adolescents | Cancer in Young Adults | Cancer Therapy | Children | Health | Leukemia